Navigation Links
Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer
Date:9/17/2013

KING OF PRUSSIA, Pa., Sept. 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and a leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced the appointment of Roberto Cuca as senior vice president and chief financial officer.

"We are delighted to have Roberto join Trevena at this pivotal juncture in the company's development," said Maxine Gowen, Ph.D., president and chief executive officer of Trevena. "Roberto's diverse experience in effectively transitioning both private and public healthcare companies through phases of rapid growth will be invaluable in assisting Trevena through its corporate and strategic evolution."

Mr. Cuca brings to Trevena nearly 20 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as Treasurer and Senior Vice President, Finance at Endo Health Solutions Inc., a specialty healthcare company. Before that, he was Director, Corporate and Business Development, at moksha8 Pharmaceuticals, Inc., a pharmaceutical company focused on emerging markets. Mr. Cuca also worked at JPMorgan Chase & Co. as an equity analyst covering U.S. pharmaceutical companies. He received an M.B.A. from the Wharton School of The University of Pennsylvania, a J.D. from Cornell Law School, an A.B. from Princeton University and he is a CFA charterholder.

"I am excited to join Trevena and work with its exceptional team at a time of such great promise," said Mr. Cuca. "The company has made significant progress in advancing its compounds into the clinic, collaborating with world-class global pharmaceutical companies and successfully securing financing to support the development of its clinical programs.  I look forward to helping the company progress towards its next phase of development."

About Biased Ligands
GPCRs are the targets of at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation.  However, traditional ligands either turn on, or turn off, all of the signaling pathways engaged by a particular receptor, which can result in efficacy limitations or undesirable adverse effects. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects.

About Trevena
Trevena, Inc. is a privately held, clinical stage pharmaceutical company that has built a pipeline of biased GPCR ligands to address unmet medical needs in cardiovascular, pain and other CNS conditions.  The company's drug discovery technology is based on extensive research from the laboratory of Nobel Prize winning scientist Robert J. Lefkowitz, M.D. of Duke University Medical Center. The lead drug in Trevena's portfolio, TRV027, is a first-in-class agent in Phase 2 testing for the treatment of acute heart failure. TRV027 is being developed by Trevena under a recently announced collaborative licensing option agreement with Forest Laboratories Inc. (NYSE: FRX). Trevena's pipeline also includes a clinical stage mu-opioid biased ligand, TRV130, in development for post-operative pain, a pre-clinical program for chronic pain, and discovery-stage programs for pain and Parkinson's disease. Trevena is based in King of Prussia, Pennsylvania and is backed by Alta Partners, Healthcare Ventures, NEA, Polaris, Forest Holdings and Yasuda Enterprise Development Company.  For more information about the company, please visit www.trevenainc.com.

For more information, please contact:
Ros Deegan, VP Business Development, Trevena Inc., 610-354-8840 x225 (Corporate)
Kimberly Minarovich, Christensen, 917-533-3268 (Media)


'/>"/>
SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
2. Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
3. Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.
4. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
5. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
6. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
7. Nephros Appoints John C. Houghton as President and Chief Executive Officer
8. Elsevier Appoints New President of Elsevier CPM Resource Center
9. GenWay Biotech Appoints New Vice President of Custom/OEM
10. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
11. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
Breaking Medicine News(10 mins):